Biological CM101 interacts with HP59 (See Wikipedia) on tumor capillary endothelium, induces complement activation and an acute inflammatory response in the tumor vasculature and surrounding tumor. Tumorend is conducting clinical trials and developing CM101 as an anti-solid tumor agent.